Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.58 · Revenue $0.00 · 7 analysts
Est. EPS $-0.62 · Revenue $0.00 · 7 analysts
Est. EPS $-2.35 · Revenue $0.00 · 7 analysts
Est. EPS $-0.66 · Revenue $0.00 · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-105.4M | -25.9% | -29.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-88.4M | -52.4% | -40.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.4% | +61.6% | -38.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 22.37x | -22.6% | +62.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $488.6M | +23.4% | +125.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.31 vs -2.20 | -4.8% | -0.66 vs -0.51 | -28.8% |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Common Stock | A | 5,000 | $7.80 |
| Sep 1, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Common Stock | D | 1,000 | $91.05 |
| Sep 1, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Common Stock | D | 4,000 | $92.01 |
| Sep 1, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Employee Warrant (right to buy) | D | 5,000 | $7.80 |
| Sep 1, 2026 | Klein Lawrence Otto | director, officer: Chief Executive Officer | Employee Warrant (right to buy) | D | 75,000 | $7.80 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Lawrence Otto Klein | President, Chief Executive Officer & Director | USD 1,080,660 | — | 1983 | Active |
Joana Goncalves | Chief Medical Officer | USD 730,980 | — | 1974 | Active |
Paul T. Quinlan | General Counsel & Secretary | USD 730,980 | Male | 1963 | Active |
Larry Todd Edwards | Chief Commercial Officer | — | Male | 1963 | Active |
Christopher Finch | Senior VP and Head of Business Development & Strategy | — | Male | — | Active |
Laura Sandler | Chief Operating Officer | — | Female | 1977 | Active |
Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls | — | — | — | Active |
Arjun Agarwal | Senior Vice President of Finance & Treasurer | — | Male | 1976 | Active |
Alan Lada | VP of IR & Capital Markets | — | Male | — | Active |
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expected to begin in 1H 2027 ORCA-SURGE Week 16 data accelerated, now expected in 1Q 2027 ORCA-SPLASH, a Phase 2 trial of ORKA-002 in moderate-to-severe hidradenitis suppurativa, initiated ORKA-004, a novel half-life extended monoclonal antibody targeting TL1A, to enter the clinic in 4Q 2026 Cash, cash equivalents and marketable securities of $1.1 billion expected to fund the Company through a BLA filing for ORKA-001
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
